Koers Mabvax Therapeutics Holdings Inc Other OTC
Aandelen
US55414P1084
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2016 | 148K 137K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,29 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,68 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,52 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 433K | Nettoschuld 2017 | 2,48 mln. 2,29 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,91% | 118 mld. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. |
- Beurs
- Aandelen
- Koers MBVXQ
- Koers